141 related articles for article (PubMed ID: 24074609)
1. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.
Nelson RE; Stenehjem D; Akerley W
Lung Cancer; 2013 Dec; 82(3):461-8. PubMed ID: 24074609
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
3. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Hornberger J; Hirsch FR; Li Q; Page RD
Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
[TBL] [Abstract][Full Text] [Related]
6. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
Grossi F; Rijavec E; Genova C; Barletta G; Biello F; Maggioni C; Burrafato G; Sini C; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
Br J Cancer; 2017 Jan; 116(1):36-43. PubMed ID: 27898657
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
10. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
11. VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
Molina-Pinelo S; Pastor MD; Paz-Ares L
Expert Rev Respir Med; 2014 Feb; 8(1):1-4. PubMed ID: 24308656
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Grossi F; Genova C; Rijavec E; Barletta G; Biello F; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
Lung Cancer; 2018 Mar; 117():64-69. PubMed ID: 29395121
[TBL] [Abstract][Full Text] [Related]
13. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C; Le Caer H; Corre R; Crequit J; Locher C; Falchero L; Dujon C; Berard H; Monnet I; Vergnenegre A
Clin Lung Cancer; 2013 Mar; 14(2):103-7. PubMed ID: 22682669
[TBL] [Abstract][Full Text] [Related]
15. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Gautschi O; Dingemans AM; Crowe S; Peters S; Roder H; Grigorieva J; Roder J; Zappa F; Pless M; Brutsche M; Baty F; Bubendorf L; Hsu Schmitz SF; Na KJ; Carbone D; Stahel R; Smit E
Lung Cancer; 2013 Jan; 79(1):59-64. PubMed ID: 23122759
[TBL] [Abstract][Full Text] [Related]
16. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
20. Third-line therapy in advanced non-small cell lung cancer.
Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
